San Diego — Otonomy, Inc, a developer of therapeutics for disorders of the ear, has appointed G. Michael Wall, PhD as vice president of product development, and Cindy Berejikian as the company’s vice president of program management. David A. Weber, PhD, was also recently appointed as CEO.
Both Wall and Berejikian reportedly possess extensive global pharmaceutical product development and commercialization expertise. Their appointments are intended to further advance Otonomy’s efforts to establish the company as a leader in the development of novel treatments for disorders of the ear.
Otonomy is currently developing OTO-104 and OTO-201, two therapies for the ear. OTO-104 is a sustained release formulation of the steroid dexamethasone. A Phase 1b clinical trial is ongoing in Meniere’s disease patients, and future studies are being planned for acute onset hearing loss.
OTO-201, the company’s second product candidate, is a novel sustained release antibiotic being developed for the treatment of recurrent otitis media in patients requiring tympanostomy tube placement. OTO-201 clinical trials are expected to begin in 2011.